Cannabinoid Encyclopedia

Health and effects

Cannabinoids and Appetite and metabolic outcomes

What studies can tell us about cannabinoids and Appetite and metabolic outcomes, including human research, early evidence, and important limits.

Updated July 2026 39 research sources Human and early research

The short answer

What does the research say about Appetite and metabolic outcomes?

Researchers have studied cannabinoids in connection with Appetite and metabolic outcomes. The current literature covers THC, CBG, and THCV. This page brings together 14 human-study sources, 15 research reviews, and 10 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. There is no single answer that applies to every cannabinoid, dose, product, or person. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Appetite and metabolic outcomes.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Appetite and metabolic outcomes covers THC, CBG, and THCV; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Appetite and metabolic outcomes

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human research included

THC

Researchers have studied THC in connection with Appetite and metabolic outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 2

Human and early-stage research

CBG

Researchers have studied CBG in connection with Appetite and metabolic outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 3

Human and early-stage research

THCV

Researchers have studied THCV in connection with Appetite and metabolic outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 4

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

14 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

15 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

10 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on Appetite and metabolic outcomes is not one kind of study. This source set includes 13 narrative or expert reviews, 10 animal studies, 7 clinical studies in people, and 4 cell or laboratory studies. 3

The recorded populations or models include people or patients (24 sources), animal models (9 sources), and cells or tissue models (2 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is appetite-related, weight, glucose, or metabolic outcomes (18 sources), appetite-related or metabolic outcomes (13 sources), and appetite or metabolic outcomes (10 sources). Closely related outcome names can still describe different measurements. 5

The Appetite and metabolic outcomes source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

systematic review or meta-analysis

Systematic review and meta-analysis of cannabinoids in palliative medicine.

On this page, this source examines THC and appetite and metabolic outcomes. 1

Study type
systematic review or meta-analysis
Population or model
people or patients
Outcome focus
appetite or metabolic outcomes
Evidence stage
evidence still limited

narrative or expert review

[Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia].

On this page, this source examines THC and appetite and metabolic outcomes. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
appetite or metabolic outcomes
Evidence stage
evidence still limited

narrative or expert review

It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.

On this page, this source examines THCV and appetite and metabolic outcomes and CBG and appetite and metabolic outcomes. 3

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
appetite-related or metabolic outcomes and appetite-related, weight, glucose, or metabolic outcomes
Evidence stage
evidence still limited

clinical study in people

Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes.

On this page, this source examines THCV and appetite and metabolic outcomes. 4

Study type
clinical study in people
Population or model
people or patients
Outcome focus
appetite-related or metabolic outcomes
Evidence stage
human research

systematic review or meta-analysis

Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome.

On this page, this source examines THC and appetite and metabolic outcomes. 5

Study type
systematic review or meta-analysis
Population or model
people or patients
Outcome focus
appetite or metabolic outcomes
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on Appetite and metabolic outcomes should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Can cannabinoids help with Appetite and metabolic outcomes?

Research exists, but there is not one answer for every cannabinoid or product. The source set includes human research as well as earlier-stage studies. 7

Why can studies reach different answers?

Studies may test different cannabinoids, doses, formulations, routes, people, and outcomes. Those differences can change the result. 8

What should I check in a study?

Check whether it studied people, what product and dose it used, what it measured, how long it lasted, and whether safety was reported. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Systematic review and meta-analysis of cannabinoids in palliative medicine. systematic review or meta-analysis; evidence still limited PubMed 29400010 DOI 10.1002/jcsm.12273
  2. 2
    [Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia]. narrative or expert review; evidence still limited PubMed 23570087
  3. 3
    It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. narrative or expert review; evidence still limited PubMed 32899626 DOI 10.3390/molecules25184036
  4. 4
    Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. clinical study in people; human research PubMed 33526143 DOI 10.1186/s42238-020-0016-7
  5. 5
    Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. systematic review or meta-analysis; evidence still limited PubMed 15050664 DOI 10.1016/j.jpainsymman.2003.09.007
  6. 6
    Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. clinical study in people; preclinical research PubMed 27503475 DOI 10.1007/s00213-016-4397-4
  7. 7
    Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. clinical study in people; human research PubMed 16849753 DOI 10.1200/jco.2005.05.1847
  8. 8
    Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. clinical study in people; human research PubMed 11599601 DOI 10.1093/jat/25.7.565
  9. 9
    Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. clinical study in people; mechanism-focused research PubMed 27573936 DOI 10.2337/dc16-0650
  10. 10
    Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. clinical study in people; human research PubMed 34569849 DOI 10.1089/can.2021.0058
  11. 11
    The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. human research PubMed 31595793 DOI 10.1177/1534735419881498
  12. 12
    Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. human research PubMed 32795544 DOI 10.1016/j.cca.2020.08.014
See all 39 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. clinical study in people; human research / 1 linked research note PubMed 33526143
  2. The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. narrative or expert review; evidence still limited / 1 linked research note PubMed 40270953
  3. It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. narrative or expert review; evidence still limited / 2 linked research notes PubMed 32899626
  4. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. clinical study in people; mechanism-focused research / 1 linked research note PubMed 27573936
  5. CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). narrative or expert review; evidence still limited / 1 linked research note PubMed 21740450
  6. SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 42196303
  7. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. animal study; mechanism-focused research / 2 linked research notes PubMed 33230154
  8. Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips. clinical study in people; mechanism-focused research / 1 linked research note PubMed 39968488
  9. The Impact of Major and Minor Phytocannabinoids on the Maintenance and Function of INS-1 β-Cells Under High-Glucose and High-Lipid Conditions. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40363798
  10. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. clinical study in people; human research / 1 linked research note PubMed 11599601
  11. [Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia]. narrative or expert review; evidence still limited / 1 linked research note PubMed 23570087
  12. Cancer cachexia and cannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 10575285
  13. Orexigenic and anabolic agents. narrative or expert review; evidence still limited / 1 linked research note PubMed 12608509
  14. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. narrative or expert review; evidence still limited / 1 linked research note PubMed 29670357
  15. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. clinical study in people; human research / 1 linked research note PubMed 16849753
  16. Systematic review and meta-analysis of cannabinoids in palliative medicine. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 29400010
  17. Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. narrative or expert review; evidence still limited / 1 linked research note PubMed 26929669
  18. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 15050664
  19. The cancer cachexia syndrome. narrative or expert review; evidence still limited / 1 linked research note PubMed 9208884
  20. The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. human research / 1 linked research note PubMed 31595793
  21. Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. narrative or expert review; evidence still limited / 1 linked research note PubMed 42105814
  22. Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat. animal study; mechanism-focused research / 1 linked research note PubMed 37305529
  23. Sphingolipid metabolism and insulin resistance - Does cannabigerol protect against experimental colitis induced by high-fat high-sucrose diet? animal study; mechanism-focused research / 1 linked research note PubMed 41056638
  24. Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited / 1 linked research note PubMed 36654096
  25. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. clinical study in people; preclinical research / 1 linked research note PubMed 27503475
  26. Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. narrative or expert review; evidence still limited / 1 linked research note PubMed 36397993
  27. A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats. animal study; preclinical research / 1 linked research note PubMed 28125508
  28. Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. clinical study in people; human research / 1 linked research note PubMed 34569849
  29. Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol. animal study; preclinical research / 1 linked research note PubMed 31035309
  30. Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus. animal study; mechanism-focused research / 1 linked research note PubMed 31941059
  31. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. human research / 1 linked research note PubMed 32795544
  32. Phytocannabinoids as novel therapeutic agents in CNS disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 21924288
  33. Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. animal study; mechanism-focused research / 1 linked research note PubMed 22543671
  34. Ensiling conditions and changes of cannabinoid concentration in industrial hemp. preclinical research / 1 linked research note PubMed 39192735
  35. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37764262
  36. Tetrahydrocannabivarin (THCV) Protects Adipose-Derived Mesenchymal Stem Cells (ASC) against Endoplasmic Reticulum Stress Development and Reduces Inflammation during Adipogenesis. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37108282
  37. High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain. animal study; mechanism-focused research / 1 linked research note PubMed 32904155
  38. Cannabigerol-A useful agent restoring the muscular phospholipids milieu in obese and insulin-resistant Wistar rats? animal study; preclinical research / 1 linked research note PubMed 38919749
  39. Cannabigerol - A potent regulator of insulin sensitivity in rat's skeletal muscle via targeting the sphingolipid metabolism and PI3K/Akt/mTOR pathway? animal study; preclinical research / 1 linked research note PubMed 40482851